5-Fluorouracil
5-Fluorouracil
Application Notes
5-Fluorouracil (5-FU) inhibits the activity of thymidylate synthetase, which affects pyrimidine synthesis and leads to depletion of intracellular TTP pools. 5-FU has also been proposed to interfere with the activity of ribosomal RNA binding protein (RRBP), at the level of pre-ribosomal RNA (pre-rRNA) processing. 5-Fluorouracil is a potent agent against solid tumors that was introduced in 1957 for clinical use. It remains one of the most effective chemotherapeutic agents in such conditions as colorectal cancer, even at its limited response rates (10 - 30%).
Usage Statement
Unless specified otherwise, MP Biomedical's products are for research or further manufacturing use only, not for direct human use. For more information, please contact our customer service department.
Key Applications
Inhibits the activity of thymidylate synthetase
SKU | 02101722-CF |
Alternate Names | 2,4-Dihydroxy-5-fluoropyrimidine; 5-Fluoro-2,4(1H,3H)-pyrimidinedione; 5-FU |
Application Notes | 5-Fluorouracil (5-FU) inhibits the activity of thymidylate synthetase, which affects pyrimidine synthesis and leads to depletion of intracellular TTP pools. 5-FU has also been proposed to interfere with the activity of ribosomal RNA binding protein (RRBP), at the level of pre-ribosomal RNA (pre-rRNA) processing. 5-Fluorouracil is a potent agent against solid tumors that was introduced in 1957 for clinical use. It remains one of the most effective chemotherapeutic agents in such conditions as colorectal cancer, even at its limited response rates (10 - 30%). |
Base Catalog Number | 101722 |
Beilstein Registry Number | 127172 |
Biochemical Physiological Actions | A potent antitumor agent that affects pyrimidine synthesis by inhibiting thymidylate synthetase thus depleting intracellular dTTP pools. It is metabolized to ribonucleotides and deoxyribonucleotides, which can be incorporated into RNA and DNA. Treatment of cells with 5-FU leads to an accumulation of cells in S-phase and has been shown to induce p53 dependent apoptosis. |
Boiling Point | Decomposes at 282-283 deg C; sublimes (0.1 mm): 190-200 deg C |
CAS # | 51-21-8 |
EC Number | 200-085-6 |
Extinction Coefficient | EmM = 7.07 (0.1 M HCl)(Lit.) |
Format | Powder |
Hazard Statements | H301-H412 |
Melting Point | Decomposes at 540-541° F (EPA, 1998) |
Molecular Formula | C4H3FN2O2 |
Molecular Weight | 130.078 g/mol |
pKa | 8.0 (Lit.) |
Purity | ~99% |
RTECS Number | YR0350000 |
Safety Symbol | GHS06 |
Solubility | less than 1 mg/mL at 66° F (NTP, 1992) |
Usage Statement | Unless specified otherwise, MP Biomedical's products are for research or further manufacturing use only, not for direct human use. For more information, please contact our customer service department. |
UV Visible Absorbance | λ max: 265 nm (Lit.) |
Vapor Pressure | 2.68X10-6 mm Hg at 25 deg C (est) |